Immitra Bio

Switzerland
Schlieren, Zurich, Switzerland

Company profile

Immitra Bio company profile

At Immitra Bio, we are developing a unique genetic medicine platform that combines two of the most powerful biomedical technologies: hematopoietic stem cells (HSCs) and CRISPR-Cas9 gene editing. Our novel technique allows for precise and long-lasting gene alterations within blood stem cells, resulting in transformational treatments for uncommon diseases with significant unmet medical needs.

Business identity

Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Founded
2024-01-01, Year

Headquarters

Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
1
Last funding
Debt Financing / $111,099 / 2025-02-27
Investors
1
Lead investors
1
Founders
1
Articles
1

Founders and investors

Founders

Jan Nelis

Lead investors

FONGIT Innovation Fund

Investors

FONGIT Innovation Fund